Polaris Pharmaceuticals Polaris Phase III interim analysis of lung mesothelioma carcinoma showed a statistically significant overall survival rate of 80% or higher for the highest grade. Posted on 2021-03-042021-03-22 by maxproadmin More >>
Polaris Pharmaceuticals Polaris Group signs collaboration agreement with Nanotein Technologies, Inc. Posted on 2020-10-062021-02-07 by maxproadmin More >>
Polaris Pharmaceuticals Polaris announces to enroll the first patient of Phase IB Clinical Trial in GBM Posted on 2020-09-172021-02-07 by maxproadmin More >>
Polaris Pharmaceuticals Polaris Group Announces officially secured USD $100 million new funding Posted on 2019-12-132021-02-07 by maxproadmin More >>
Polaris Pharmaceuticals Polaris Group ADI-PEG20 on the cover of AACR journals Posted on 2019-12-102021-02-07 by maxproadmin More >>
